Index Investing News
Thursday, May 29, 2025
No Result
View All Result
  • Login
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
No Result
View All Result
Index Investing News
No Result
View All Result

Acrivon: Precision-Testing Your Trial Patients Before Enrolment (NASDAQ:ACRV)

by Index Investing News
March 26, 2023
in Stocks
Reading Time: 4 mins read
A A
0
Home Stocks
Share on FacebookShare on Twitter


Dilok Klaisataporn/iStock via Getty Images

Acrivon (NASDAQ:ACRV) develops precision cancer medicines and then uses its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3, to match patients whose tumors are sensitive to that medicine. This leads to a drug-specific companion diagnostics called OncoSignature. Lead candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2. ACR-368 is currently in a potentially registrational Phase 2 trial across multiple tumor types. Other programs are preclinical.

ACR-368 has been licensed from Eli Lilly & Co. (LLY) in an all-equity deal. It is a clinically active phase 2 Damage Response (DDR) inhibitor with a tested 15-20% ORR. Acrivon’s goal is to use its OncoSignature diagnostic and patient selection platform to improve these ORR figures. They are running a phase 2 trial with an intent to convert this to a registrational trial if possible. There are phase 2 trials in Platinum-Resistant Ovarian Cancer, Endometrial Cancer, Bladder Cancer and HPV+ SCC (anal, H&N and cervical cancer) for ACR-368 monotherapy in OncoSignature-positive patients. There are exploratory phase 1b/2 single arm trials of ACR-368 in combination with low dose gemcitabine, or LDG, in OncoSignature-negative patients.

Acrivon is a recent IPO launched last November amidst some of the worst periods in biotech, forever to be known as the biotech winter. ACR-368 originates in research done since 2001 in a collaboration between Array Biopharma and Icos, where it was known as prexasertib. After Lilly acquired Icos, and Pfizer (PFE) acquired Array, Lilly continued with its trials of prexasertib, just as Roche continued trials of another CHK-1 inhibitor, RG7741, which also began life at Array. Trials saw ORR of 15-20%, but Roche discontinued work with RG7741 in 2018, and Lilly followed a year later.

Drug activity was observed in some 30% of ovarian cancer patients sensitive to prexasertib, however the ORR, as we can see, was relatively poor. According to Acrivon, “29% at the single center Phase 2 ovarian cancer trial at NCI in the intent to treat, or ITT, population, and approximately 12% across the platinum-resistant ovarian cancer cohorts in the large Phase 2 multi-center international trial sponsored by Lilly.” Acrivon’s idea is to use this old molecule with its OncoSignature platform and try to identify patients in whom the ORR rate can be improved. Data is supposed to come in mid-2023. However, it is important to remember that prexasertib will have no real patent protection, and the only protection we can expect is through a mix of method and via Oncosignature patents.

The idea is interesting, and potentially doable. A lot of promising drugs fail in phase 2 trials because patients are selected by indication and prior treatment modalities and so on, and not through whether they are sensitive to the tested medicine. Nowadays, patients are tested for certain genetic situations, like if they have a BRAF mutation, and given precision drugs that address those mutations. Acrivon is extending that concept beyond genetics, and using their proprietary testing methodology, they are testing patients before they join the trial. If the patient is sensitive to the test, they are included; if not, they are excluded. This, according to the CEO, is, among other things, a way to avoid overtreatment in these late stage patients, as well as to improve trial results by only including those patients who have a higher possibility of responding to the tested drug.

Not a lot of details are available about the AP3 platform. In their S1, the company states:

Our ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from patients with ovarian cancer treated with ACR-368 in past Phase 2 clinical trials conducted by Eli Lilly and Company, or Lilly, and at the National Cancer Institute, or NCI, demonstrating robust enrichment of responders through our method.

So while this does not divulge precisely how AP3 works, including what the 3 biomarkers are for selecting patient responders, it tells us that the platform was tested on ACR-368 thoroughly, and found to be useful, in preclinical and other model studies. Because ACR-368 has been tested in over 400 patients, has seen durable responses including CRs, and has been generally well-tolerated, the company was able to jump directly into a potentially registrational phase 2 trial with the FDA’s blessings.

The company also used its platform to identify resistance mechanisms in certain tumors. The company discovered that low dose gemcitabine can overcome some of these resistances and further sensitize these tumors to ACR-368 by inducing increased DDR stress. The company will incorporate these ideas into further trials in OncoSignature-negative patients.

Financials

ACRV, a recent IPO, has a market cap of $273mn, a stock price of $13, and a cash reserve of $170mn. There are financial statements from September 2022 – here – where cash shown is some $77mn. To this has been added the IPO funds, and we have the $170mn as of December 2022. R&D/G&A are from before the IPO, and these are $8mn and $2mn approximately and respectively. However, these figures are not reliable because the company will soon launch a phase 2 trial and will also have considerable other costs. The company guides for a cash runway till Q4 2024, so we will have to go with that.

The stock went up 30% post IPO, but between February and March 7, it plunged back down 30% on very high volume on a single day. There was no news. It will probably turn out to be the sound of early investors leaving.

Bottomline

The company is interesting, and everything is predicated on the AP3 platform thing about which we know very little. The company has chosen not to divulge. They have patent coverage for the platform, and some coverage from the unlicensed molecule as well. Their cash balance is okay but will need replenishing. Their logic is sound – somebody needs to make clinical trials more efficient – however we need to really wait a lot longer before we see some validation of their claims. As is my usual style, I will choose not to get excited too early.



Source link

Tags: AcrivonEnrolmentNASDAQACRVpatientsPrecisionTestingTrial
ShareTweetShareShare
Previous Post

Active Vs Passive Income And How They Work For You

Next Post

Vande Bharat Express trains in India: Full list and stoppage points, timings and ticket price | Indian Railways

Related Posts

PayPal Holdings, Inc. (PYPL) Bernstein forty first Annual Strategic Choices Convention (Transcript)

PayPal Holdings, Inc. (PYPL) Bernstein forty first Annual Strategic Choices Convention (Transcript)

by Index Investing News
May 28, 2025
0

PayPal Holdings, Inc. (NASDAQ:PYPL) Bernstein forty first Annual Strategic Choices Convention Might 28, 2025 9:00 AM ET Firm Individuals Alex...

Attire Insider: Knowledge and Tendencies for Resellers (2025)

Attire Insider: Knowledge and Tendencies for Resellers (2025)

by Index Investing News
May 28, 2025
0

Most of the world’s main manufacturers and retailers depend on B-Inventory—the world’s largest B2B recommerce platform—to shortly and effectively resell...

Baird Small/Mid Cap Development Fairness Fund Q1 2025 Commentary

Baird Small/Mid Cap Development Fairness Fund Q1 2025 Commentary

by Index Investing News
May 28, 2025
0

This text was written byObserveBaird is a world monetary companies agency offering Personal Wealth Administration, Belief, Asset Administration, Funding Banking,...

Semtech Company 2026 Q1 – Outcomes – Earnings Name Presentation (NASDAQ:SMTC)

Semtech Company 2026 Q1 – Outcomes – Earnings Name Presentation (NASDAQ:SMTC)

by Index Investing News
May 28, 2025
0

This text was written byObserveLooking for Alpha's transcripts workforce is answerable for the event of all of our transcript-related initiatives....

“Previous-Original” Technical Evaluation Factors To Warning (SPX)

“Previous-Original” Technical Evaluation Factors To Warning (SPX)

by Index Investing News
May 27, 2025
0

This text was written byObserveMichael James McDonald is a inventory market forecaster, creator and former Senior Vice President of Investments...

Next Post
Vande Bharat Express trains in India: Full list and stoppage points, timings and ticket price | Indian Railways

Vande Bharat Express trains in India: Full list and stoppage points, timings and ticket price | Indian Railways

Drafting a road map to bolster the pharma sector

Drafting a road map to bolster the pharma sector

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

10 years of rally in U.S. house prices could end, says Robert Shiller

10 years of rally in U.S. house prices could end, says Robert Shiller

July 24, 2023
5 Chelsea gamers and switch targets who may very well be their new Didier Drogba

5 Chelsea gamers and switch targets who may very well be their new Didier Drogba

February 28, 2025
Save Your Way to an Early Retirement

Save Your Way to an Early Retirement

September 27, 2022
Analyst Predicts 0,000 Peak Before Halving Event

Analyst Predicts $100,000 Peak Before Halving Event

February 11, 2024
Slower financial progress is probably going forward with threat of a recession rising, in line with the CNBC Fed Survey

Slower financial progress is probably going forward with threat of a recession rising, in line with the CNBC Fed Survey

March 18, 2025
Golar LNG (GLNG): A Prime Inventory To Personal

Golar LNG (GLNG): A Prime Inventory To Personal

March 25, 2022
FirstFT: Global regulators set sights on stricter banking rules

FirstFT: Global regulators set sights on stricter banking rules

April 17, 2023
There Are A Lot Of Actually Weird Theories About Monkeypox Going Round – Funding Watch

There Are A Lot Of Actually Weird Theories About Monkeypox Going Round – Funding Watch

May 23, 2022
Index Investing News

Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.

  • 1717575246.7
  • Browse the latest news about investing and more
  • Contact us
  • Cookie Privacy Policy
  • Disclaimer
  • DMCA
  • Privacy Policy
  • Terms and Conditions
  • xtw18387b488

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In